Chronic congestive heart failure (CHF) is the primary cause of hospitalization in people over the age of 65, affecting about 26 million people globally. The related cost in the United States alone is estimated at up to $40 billion. About half that amount stems from hospital readmissions — 25 percent of heart-failure patients are readmitted within a month, and half within six months.
Israeli devices such as Impulse Dynamics’ Optimizer III and BioControl Medical’s CardioFit offer novel treatment options for CHF.
Here we’ll take a look at some Israeli companies developing better ways to manage and monitor this progressive condition, to improve patients’ quality of life and avoid repeated hospitalizations.
Vectorious Medical Technologies of Tel Aviv recently closed a $5 million financing round for the development of its miniature wireless hemodynamic monitoring sensory implant toward first human trials. Among the investors is the Global Cardiovascular Innovation Center of the Cleveland Clinic.
More...
